CN1216613C - 一种具有调节血脂作用的保健品及制备方法 - Google Patents
一种具有调节血脂作用的保健品及制备方法 Download PDFInfo
- Publication number
- CN1216613C CN1216613C CN 01113266 CN01113266A CN1216613C CN 1216613 C CN1216613 C CN 1216613C CN 01113266 CN01113266 CN 01113266 CN 01113266 A CN01113266 A CN 01113266A CN 1216613 C CN1216613 C CN 1216613C
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- ethanol
- health
- rhizoma alismatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000001105 regulatory effect Effects 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 54
- 210000004369 blood Anatomy 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 26
- 150000002632 lipids Chemical class 0.000 claims abstract description 17
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 15
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 15
- 235000020712 soy bean extract Nutrition 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 230000036541 health Effects 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 235000015468 Lycium chinense Nutrition 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 229930003944 flavone Natural products 0.000 claims description 10
- 235000011949 flavones Nutrition 0.000 claims description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002212 flavone derivatives Chemical class 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims description 6
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims description 6
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000005202 decontamination Methods 0.000 claims description 3
- 230000003588 decontaminative effect Effects 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 241000748223 Alisma Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
序号 | 性别 | 年龄 | 胆固醇mmol/L(3.10-5.17) | 甘油三酯mmol/L(0.56-2.30) | 高密脂蛋白mmol/L(0.90-1.50) | 低密脂蛋白mmol/L(0.00-3.36) | |
1 | 男 | 54 | 服用前 | 3.79 | 2.43 | 1.33 | 2.40 |
服用后 | 4.23 | 1.26 | 1.45 | -- | |||
2 | 女 | 60 | 服用前 | 5.32 | 3.09 | 1.23 | 3.20 |
服用后 | 5.14 | 1.34 | 1.47 | -- | |||
3 | 男 | 34 | 服用前 | 5.23 | 1.85 | 0.95 | 3.70 |
服用后 | 5.09 | 1.57 | 1.03 | -- | |||
4 | 男 | 32 | 服用前 | 3.94 | 2.44 | 1.32 | 2.60 |
服用后 | 4.17 | 1.04 | 1.44 | -- | |||
5 | 男 | 29 | 服用前 | 5.56 | 2.74 | 1.50 | 3.60 |
服用后 | 5.61 | 1.37 | 1.47 | 3.00 | |||
6 | 男 | 66 | 服用前 | 6.60 | 2.05 | 1.50 | 4.70 |
服用后 | 5.82 | 0.92 | 1.21 | 4.10 | |||
7 | 女 | 59 | 服用前 | 6.20 | 2.57 | 1.50 | 4.60 |
服用后 | 6.45 | 2.00 | 1.42 | -- | |||
8 | 男 | 35 | 服用前 | 5.68 | 1.88 | 1.50 | 4.30 |
服用后 | 4.87 | 1.37 | 0.91 | 3.10 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01113266 CN1216613C (zh) | 2001-07-05 | 2001-07-05 | 一种具有调节血脂作用的保健品及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01113266 CN1216613C (zh) | 2001-07-05 | 2001-07-05 | 一种具有调节血脂作用的保健品及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1394614A CN1394614A (zh) | 2003-02-05 |
CN1216613C true CN1216613C (zh) | 2005-08-31 |
Family
ID=4660001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01113266 Expired - Lifetime CN1216613C (zh) | 2001-07-05 | 2001-07-05 | 一种具有调节血脂作用的保健品及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1216613C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1325089C (zh) * | 2005-02-06 | 2007-07-11 | 杭州鑫富药业有限公司 | 一种中成药或保健食品组合物及其应用 |
CN102524795A (zh) * | 2010-12-17 | 2012-07-04 | 武汉金肽堂生物科技有限公司 | 纳豆芽孢杆菌及其在制备具有血栓溶解性保健食品中的应用 |
CN102872306B (zh) * | 2012-09-25 | 2014-04-09 | 深圳市安美信生物医药科技有限公司 | 治疗心脑血管疾病的复方富硒中药组合物及其制备方法 |
CN104172167A (zh) * | 2014-08-20 | 2014-12-03 | 陕西华州医药生物工程有限公司 | 一种降血脂功能食品及其制备方法 |
CN111184185A (zh) * | 2020-01-15 | 2020-05-22 | 宁夏医科大学 | 一种具有调血脂作用的组合物及其制备方法和用途 |
-
2001
- 2001-07-05 CN CN 01113266 patent/CN1216613C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1394614A (zh) | 2003-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1236792C (zh) | 防治脑病和益智的脑活性作用物质及其制备方法 | |
CN1283258C (zh) | 一种抗肝纤维化的药物及其制备方法 | |
CN101181351B (zh) | 一种抗疲劳、增强免疫的中药组合物及其制备方法 | |
CN105395919A (zh) | 一种含有黑木耳提取物、具有降血脂作用的组合物及其制备方法 | |
CN100558347C (zh) | 人参北芪分散片制剂及其制备工艺 | |
CN106214773A (zh) | 一种对化学性肝损伤有辅助保护功能的组合物及其制备方法 | |
CN1883623A (zh) | 一种降脂复方中药及其制备方法 | |
CN1216613C (zh) | 一种具有调节血脂作用的保健品及制备方法 | |
CN1069542C (zh) | 一种治疗慢性肝病的药物及其制备方法 | |
CN1872134A (zh) | 一种苦瓜多糖降血糖组合物及其制备方法 | |
CN1256133C (zh) | 一种抗疲劳的中药组合物及其制备方法 | |
CN114470042B (zh) | 一种防治动物肝损伤的组合物及其制备方法和用途 | |
CN1067258C (zh) | 猕猴桃根及其有效部位的用途 | |
CN1709462A (zh) | 人参北芪胶囊制剂及其制备工艺 | |
CN1611232A (zh) | 一种以抗疲劳、抗辐射、抗忧郁为主功效的药物组合物及其制法 | |
CN1709415A (zh) | 石刁柏提取物及其制备方法 | |
CN1159029C (zh) | 一种调脂药物及其制备方法 | |
CN101385783A (zh) | 一种治疗急慢性肝病的护肝宁丸及其制备方法 | |
CN1237998C (zh) | 治疗小儿咳喘的泡腾片 | |
CN1250244C (zh) | 一种防治高脂血症的组合物 | |
CN106262805A (zh) | 一种用于防治高血脂的组合物及其制备方法 | |
CN1239159C (zh) | 降血脂药物组合物 | |
CN1686112A (zh) | 蛇床子素的用途及用于治疗脂肪肝的制剂 | |
CN1672719A (zh) | 首乌在制备治疗脂肪肝病药物中的应用 | |
CN1186030C (zh) | 用于使哺乳动物体重减重的组合物,含它的产品及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN TAITAI MEDICINE CO., LTD. Free format text: FORMER OWNER: SHENZHENG TAITAN MEDICINE INDUSTRY CO., LTD. Effective date: 20030514 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030514 Address after: 518057 Nanshan Fifth Industrial Zone, Guangdong, Shenzhen Applicant after: Shenzhen Taitai Pharmaceutical Industry Co., Ltd. Address before: 518008, Guangdong, Shenzhen province Shennan East Road, No. 5002 Hing Plaza Plaza, Wang commercial center commercial building 23 floor Applicant before: Shenzhen Taitai Pharmaceutical Industry Co. Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20050831 |
|
CX01 | Expiry of patent term |